Arnab Chakravarti MD

Arnab Chakravarti MD
ChairCollege of
080B James Cancer Hosp & Res Inst 300 W 10th Avenue Columbus Ohio 43210
  • Translational Therapeutics

Research Description

Dr. Chakravarti’s Research Group is comprised of multiple faculty members and has a primary focus of investigating the molecular, genetic, and epigenetic mechanisms of treatment resistance in human tumors and developing strategies to circumvent this resistance in the clinic. A major focus of the group is on signal transduction pathways, specifically the PI3K/AKT pathway, in glioblastoma and prostate cancer. Dr. Chakravarti is an internationally-recognized cancer researcher and has received continuous federal funding since 1999 to support his research activities.

Current Publications

  • Palanichamy K, Chakravarti A, Houghton PJ, Singh M, Leasure JM, Chronowski C, Geier B, Bondra K, Duan W, Hensley LA, Villalona-Calero M, Li N, Vergis AM, Kurmasheva RT, Shen C, Woods G, Sebastian N, Fabian D, Kaplon R, Hammond SFANCD2 Is a Potential Therapeutic Target and Biomarker in Alveolar Rhabdomyosarcoma Harboring the PAX3-FOXO1 Fusion Gene.Clin Cancer Res 20 3884-95 7/15/2014
  • Ferrarese R, Harsh GR 4th, Yadav AK, Bug E, Maticzka D, Reichardt W, Dombrowski SM, Miller TE, Masilamani AP, Dai F, Kim H, Hadler M, Scholtens DM, Yu IL, Beck J, Srinivasasainagendra V, Costa F, Baxan N, Pfeifer D, von Elverfeldt D, Backofen R, Weyerbrock A, Duarte CW, He X, Prinz M, Chandler JP, Vogel H, Chakravarti A, Rich JN, Carro MS, Bredel MLineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression.J Clin Invest 124 2861-76 7/1/2014
  • Yan F, Alinari L, Chiocca EA, Li C, Sif S, Jacob S, Lawler S, Kaur B, Baiocchi RA, Lustberg ME, Martin LK, Cordero-Nieves HM, Banasavadi-Siddegowda Y, Virk S, Barnholtz-Sloan J, Bell EH, Wojton J, Jacob NK, Chakravarti A, Nowicki MO, Wu X, Lapalombella R, Datta J, Yu B, Gordon K, Haseley A, Patton JT, Smith PL, Ryu J, Zhang X, Mo X, Marcucci G, Nuovo G, Kwon CH, Byrd JCGenetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.Cancer Res 74 1752-65 3/15/2014
  • Chakravarti AEditorial on "targeting Wee1 for the treatment of pediatric high-grade gliomas".Neuro Oncol 16 325 3/1/2014
  • Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP, Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti AA randomized trial of bevacizumab for newly diagnosed glioblastoma.N Engl J Med 370 699-708 2/20/2014
  • Bell EH, Mischel P, Chakravarti A, Guo DTargeting SREBP-1-driven lipid metabolism to treat cancer.Curr Pharm Des 20 2619-26 1/1/2014
  • Chakravarti A, Quick AM, Rong Y, Walston S, Welliver MXImproving intra-fractional target position accuracy using a 3D surface surrogate for left breast irradiation using the respiratory-gated deep-inspiration breath-hold technique.PLoS One 9 e97933 1/1/2014
  • Juratli TA, Engellandt K, Lautenschlaeger T, Geiger KD, von Kummer R, Cerhova J, Chakravarti A, Krex D, Schackert GIs there pseudoprogression in secondary glioblastomas?Int J Radiat Oncol Biol Phys 87 1094-9 12/1/2013
  • Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ Jr, Mehta MPDose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.J Clin Oncol 31 4085-91 11/10/2013
  • Chettiar SN, Cooley JV, Park IH, Bhasin D, Chakravarti A, Li PK, Li C, Jacob NKDesign, synthesis and biological studies of survivin dimerization modulators that prolong mitotic cycle.Bioorg Med Chem Lett 23 5429-33 10/1/2013
  • Meng W, Ye Z, Cui R, Perry J, Dedousi-Huebner V, Huebner A, Wang Y, Li B, Volinia S, Nakanishi H, Kim T, Suh SS, Ayers LW, Ross P, Croce CM, Chakravarti A, Jin VX, Lautenschlaeger TMicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma.Clin Cancer Res 19 5423-33 10/1/2013
  • Chakravarti A, Bhargava RLymphangioma circumscriptum of the tongue in children: successful treatment using intralesional bleomycin.Int J Pediatr Otorhinolaryngol 77 1367-9 8/1/2013
  • Shirai K, Mizui T, Suzuki Y, Okamoto M, Hanamura K, Yoshida Y, Hino M, Noda SE, Al-jahdari WS, Chakravarti A, Shirao T, Nakano TX irradiation changes dendritic spine morphology and density through reduction of cytoskeletal proteins in mature neurons.Radiat Res 179 630-6 6/1/2013
  • Lautenschlaeger T, George A, Klimowicz AC, Efstathiou JA, Wu CL, Sandler H, Shipley WU, Tester WJ, Hagan MP, Magliocco AM, Chakravarti ABladder preservation therapy for muscle-invading bladder cancers on Radiation Therapy Oncology Group trials 8802, 8903, 9506, and 9706: vascular endothelial growth factor B overexpression predicts for increased distant metastasis and shorter survival.Oncologist 18 685-6 6/1/2013
  • Carbone DP, Chakravarti AFrom the guest editors: management of locally advanced lung cancer.Cancer J 19 199 5/1/2013
  • Guo D, Bell EH, Chakravarti ALipid metabolism emerges as a promising target for malignant glioma therapy.CNS Oncol 2 289-299 5/1/2013
  • Chakravarti A, Wang M, Robins HI, Lautenschlaeger T, Curran WJ, Brachman DG, Schultz CJ, Choucair A, Dolled-Filhart M, Christiansen J, Gustavson M, Molinaro A, Mischel P, Dicker AP, Bredel M, Mehta MRTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients.Int J Radiat Oncol Biol Phys 85 1206-11 4/1/2013
  • Lawrence YR, Vikram B, Dignam JJ, Chakravarti A, Machtay M, Freidlin B, Takebe N, Curran WJ Jr, Bentzen SM, Okunieff P, Coleman CN, Dicker APNCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.J Natl Cancer Inst 105 11-24 1/2/2013
  • Ru P, Williams TM, Chakravarti A, Guo DTumor metabolism of malignant gliomas.Cancers (Basel) 5 1469-84 1/1/2013
  • Meng W, McElroy JP, Volinia S, Palatini J, Warner S, Ayers LW, Palanichamy K, Chakravarti A, Lautenschlaeger TComparison of microRNA deep sequencing of matched formalin-fixed paraffin-embedded and fresh frozen cancer tissues.PLoS One 8 e64393 1/1/2013
  • Jacob NK, Cooley JV, Yee TN, Jacob J, Alder H, Wickramasinghe P, Maclean KH, Chakravarti AIdentification of sensitive serum microRNA biomarkers for radiation biodosimetry.PLoS One 8 e57603 1/1/2013
  • Lautenschlaeger T, Perry J, Peereboom D, Li B, Ibrahim A, Huebner A, Meng W, White J, Chakravarti AIn vitro study of combined cilengitide and radiation treatment in breast cancer cell lines.Radiat Oncol 8 246 1/1/2013
  • Sanchez C, Sahin A, Futalan D, Gonda DD, Scheer JK, Akers J, Palanichamy K, Waterman P, Chakravarti A, Weissleder R, Morse B, Marsh N, Furfine E, Chen CC, Carvajal I, Carter BS, Waters JDCT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy.J Neurooncol 110 37-48 10/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: